BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

Contributed by: Business Wire

Tags

Oncology

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

ESMO 2026

More Like This

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day